BERLIN (AP) â Pharmaceutical company BioNTech said Monday that it wants to use the mRNA technology behind its coronavirus vaccine to target malaria. The Germany-based company, which developed the first widely approved coronavirus shot together with U.S. partner Pfizer, aims to begin clinical trials for a âsafe and highly effective malaria vaccineâ by the end of next year. âWe are already working on HIV and and tuberculosis, and malaria is the third big indication (disease) with a high unmet medical need,â BioNTech's chief executive, Ugur Sahin, told The Associated Press. âIt has an incredible high number of people being infected every year, a high number of patients dying, a particularly severe disease and high mortality in small children.â